GDP chemotherapy

DRUG2 trials

Sponsors

Chinese Academy of Medical Sciences

Conditions

Lymphoma, T-Cell, PeripheralStage I/II Extranodal NK/T-cell Lymphoma

Phase 2

Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma

CompletedNCT02276248

Chinese Academy of Medical SciencesStage I/II Extranodal NK/T-cell Lymphoma

Start: 2010-06-30End: 2016-12-31Updated: 2017-08-16

GDP in Frontline Chemotherapy for Patients With PTCL-NOS

Chinese Academy of Medical SciencesLymphoma, T-Cell, Peripheral

Start: 2011-01-31End: 2016-12-31Target: 28Updated: 2016-07-26

Related Papers

Phase II clinical trial of first-line combination of radiation followed by gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy for early-stage extranodal natural killer/T-cell lymphoma with unfavorable prognostic factors: The GREEN study (NCT02276248).

Journal of Clinical Oncology2017-05-20